Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Telix Pharmaceuticals (TLX) Total Liabilities (2023 - 2025)

Telix Pharmaceuticals has reported Total Liabilities over the past 3 years, most recently at $748.6 million for Q4 2025.

  • Quarterly Total Liabilities rose 20.73% to $748.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $748.6 million through Dec 2025, up 20.73% year-over-year, with the annual reading at $748.6 million for FY2025, 27.44% up from the prior year.
  • Total Liabilities was $748.6 million for Q4 2025 at Telix Pharmaceuticals, up from $620.1 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $748.6 million in Q4 2025 and troughed at $167.3 million in Q4 2023.
  • The 3-year median for Total Liabilities is $620.1 million (2024), against an average of $512.0 million.
  • Year-over-year, Total Liabilities soared 270.57% in 2024 and then increased 20.73% in 2025.
  • A 3-year view of Total Liabilities shows it stood at $167.3 million in 2023, then surged by 270.57% to $620.1 million in 2024, then increased by 20.73% to $748.6 million in 2025.
  • Per Business Quant, the three most recent readings for TLX's Total Liabilities are $748.6 million (Q4 2025), $620.1 million (Q4 2024), and $167.3 million (Q4 2023).